Google
×
May 16, 2020 · KPC34 is a novel phospholipid mimetic that when cleaved by phospholipase C (PLC) liberates gemcitabine monophosphate and a diacylglycerol ...
People also ask
KPC34 acts independently of ENT1 and dCK. KPC34 was active against all AML cell lines tested with IC50s in the nanomolar range. Enforced expression of PLC ...
KPC34 was cytotoxic against a panel of ALL cell lines with IC50s in the nano-molar range but was particularly effective against the two Ph+ ALL cell lines.
Nov 15, 2013 · KPC34 is a novel phospholipid conjugate of the deoxycytidine analog gemcitabine. Gemcitabine acts similarly to cytarabine and is administered IV ...
Jul 1, 2017 · KPC34's novel properties result in improved pharmacokinetics. It overcomes chemoresistance to Ara-C by bypassing ENT-1 uptake and dCK activation ...
Nov 15, 2013 · KPC34 is a novel phospholipid conjugate of the deoxycytidine analog gemcitabine. Gemcitabine acts similarly to cytarabine and is ...
Cytarabine (Ara-C) has been a major drug for acute myeloid leukemia (AML) treatment for more than three decades. But KPC34 has shown superior results when ...
KPC-34. Definition, Carbapenem-hydrolyzing class A beta-lactamase kpc-34 [Klebsiella pneumoniae] Accession: WP_109545044.1. AMR Gene Family, KPC beta-lactamase.
KPC34 is a first-in class, novel phospholipid co-drug that is composed of 2 active moieties. It combines a classic DNA damaging agent with a kinase ...
We encapsulated this regimen in FDA approved poly(lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-PEG) NPs to reduce systemic side effects, enhance ...